Parkinson Disease
Conditions
Keywords
Parkinson disease, observational, longitudinal
Brief summary
The purpose of this study is to longitudinally follow consenting clinical trial participants who participated in PRECEPT (A Randomized, Double Blind, Placebo Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP 1347 in Patients With Early Parkinson's Disease). The study will assess the clinical and imaging outcomes relevant to the natural history of Parkinson's disease (PD), as well as determine early biomarkers of the disease.
Interventions
None listed
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS)
H. Lundbeck A/S
Parkinson's Disease Foundation
United States Department of Defense
The Parkinson Study Group
Study design
Observational model
COHORT
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participation in the PRECEPT study * Willing and able to give informed consent
Exclusion criteria
* Patients will be excluded from participating in the the study if either of the criteria stated above is not met
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Unified Parkinson Disease Rating Scale (UPDRS) and β-CIT SPECT imaging of the dopamine transporter. | Annual, ongoing assessments |
Secondary
| Measure | Time frame |
|---|---|
| University of Pennsylvania Smell Identification Test (UPSIT) | Annual, ongoing assessments |
Countries
Canada, United States
Outcome results
None listed